• 20+ years of experience in research and development and company management in the pharmaceutical industry.
• Former CEO and CSO of BioDuro, a PPD Company.
• Former Head of Early Development Team, Cardiovascular Diseases at Merck US.
• Former Fellow at The Howard Hughes Medical Institute.
• The 17th President of the Sino-American Pharmaceutical Professional Association (SAPA).

• 28 year’ experience in global clinical development of new drugs.
• Former Senior Director at Roche American Clinical Pharmacology and Translational Medicine Center.
• Former Senior Associate Director of Clinical Pharmacology at Pfizer.
• Fellow of Gastroenterology Department, School of Medicine, University of Missouri-Kansas City, USA.
• Ph.D. in Pharmacy, School of Pharmacy, University of Missouri-Kansas City, USA.

• 20 years’ experience in investment analysis and management of the healthcare industry.
• Former Executive Director, Equity Research Analyst at UBS AG.
• Former Director, Equity Research Analyst at Merrill Lynch Asia (Hong Kong).
• Former Senior Analyst at Mehta Partners LLC (New York).
• Former Research Scientist at CADUS Pharmaceutical Inc.
• Master’s in chemistry, University of Pittsburgh; MBA, New York University.

• More than 20 years of drug discovery experience.
• Former Executive Director of Medicinal Chemistry at BioDuro, a PPD company.
• Former Principal Scientist at Pfizer.
• Ph.D. in Organic Chemistry at Emory University.

More than 24 years’ solid experience in production commercialization

Former General Manager of Core Product Division at Sanofi (China)

Former General Manager of Abbott Diabetes Care and Head of Greater China in Abbott

Former Head of Novartis Chengdu Branch

EMBA from Peking University

• More than 20 years of drug discovery experience in Immunology.
• Former Senior Director of Discovery Biology at BioDuro, a PPD company.
• Former Senior Principle Scientist at BMS.
• Ph.D. from University of Arkansas, USA.

• More than 20 years’ experience in non-clinical safety evaluation of innovative drugs.
• Former Director of Safety Assessment at GSK and J&J.
• Council member of Drug Safety Evaluation and TCM Specialty Sections, Chinese Society of Toxicology.
• Board certified toxicologist (DABT) in the US.
• Ph.D. in Toxicology from University of Illinois at Chicago, College of Pharmacy.

• More than 15 years of drug discovery experience.
• Former Director of Discovery Biology at BioDuro, a PPD company.
• Former Principal Scientist in skin biology at J&J.
• Ph.D. from Johns Hopkins School of Medicine.

• More than 20 years of drug discovery experience.
• Former Executive Director of Medicinal Chemistry at Pharmaron.
• Former Senior Principle Scientist at Roche.
• Ph.D. in Organic Chemistry at University of Alberta, Canada.

• More than 12 years’ experience in drug R&D and pharmaceutical plant operation management.
• Former President Assistant and Head of an API plant of the Yangtze River Pharmaceutical Group.
• Former Director of the State Key Laboratory of New Drug Formulation Technology.
• Ph.D. from Changchun Institute of Applied Chemistry, CAS.

Dr. Shi is a distinguished structural biologist, and his research is focused on molecular mechanism of apoptosis, membrane protein structure and function as well as the structure and function of macromolecular machineries.

• President and Founder, Westlake University.
• Academician, Chinese Academy of Sciences; Honorary Foreign Member, American Academy of Arts and Sciences, USA; Foreign Associate, National Academy of Sciences, USA; Foreign Associate, European Molecular Biology Organization.
• Recipients of Qiushi Outstanding Scientist Award, Ho Leung Ho Lee Lifetime Achievement Award, Raymond and Beverly Sackler International Prize, and the Gregory Aminoff Prize.

Dr. Zhang is a renowned professor in cancer genomics and bioinformatics, with his current research focusing on using cutting edge technologies such as single cell sequencing to understand oncogenesis and cancer immunology. He has rich experiences in both academia and biotechnology industry and is a holder of many US patents on cancer targets.

• Associate Director of BIOPIC，College of Life Sciences, Peking University; Senior Principle Investigator of Peking-Tsinghua University Center of Life Sciences.
• Former Head and Lead Scientist of the Bioinformatics division of Genentech Inc., USA.

Dr. Li is a renowned specialist in rheumatoid immunotherapy. His main research areas include the pathogenesis of rheumatoid arthritis and the early diagnosis and the treatment of immune-intervention, systemic lupus erythematosus and Sjogren syndrome.

• Director of the Clinical Immunology Center/Rheumatism Immunology Department, Peking University People’s Hospital.
• Director of Clinical Immunology Branch of China Immunology Association; Chairman of APLAR.
• Editor-in-chief of Chinese Journal of Rheumatology and the Chinese edition of “Nat Rev Rheum”.
• Recipient of National Outstanding Youth Fund Award, 973 Chief Scientist, Distinguished Professor of CMB and Wu Yang Award.

Dr. Arnold Levine is a widely acclaimed leader in cancer research. In 1979, Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development.

• Professor Emeritus in Natural Science, Institute for Advanced Study (IAS).
• Academician of National Academy of Sciences USA, National Academy of Medicine USA.
• Former professor at The Rockefeller University, Princeton University.
• Recipients of Louisa Gross Horwitz Prize, 1998；Keio Medical Science Prize, 2000；First Recipient of the Albany Medical Center Prize in Medicine and Biomedical Research, 2001.

James Deng is a renowned Advisor Board Member of InnoCare in Sales & Marketing. Mr. Deng is a management expert in medical field with 30 years management experience in global pharmaceutical and medical device companies.

• Senior Vice President, BD USA; General Manager, BD Greater China.
• Deputy Head of Healthcare Industry Division, China Health Economics Association.
• Former VP Marketing, Novartis Pharma US; CEO & President, Novartis Pharma China.
• Founding and elected AdvaMed China Board Chair for four consecutive term.